FDA advisers endorse Eli Lilly’s early-stage Alzheimer’s drug donanemab
On Monday, a panel of independent advisers to the US Food and Drug Administration voted to endorse Eli Lilly’s drug donanemab, a monoclonal antibody designed to slow the progression of early symptomatic Alzheimer’s disease,